Top Page
Cronos Australia Ltd.
(Sydney:VIT)
Cronos Australia Ltd. (VIT) vs. iShares MSCI Australia ETF (EWA)
Cronos Australia Ltd. Business Overview & Revenue Model
Cronos Australia Ltd. Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 129.24M | 124.04M | 123.87M | 117.34M | 66.99M | 21.71M |
| Gross Profit | 19.87M | 33.75M | 34.22M | 25.96M | 25.43M | 3.19M |
| EBITDA | 4.15M | 5.64M | 7.08M | 21.08M | 10.87M | 2.12M |
| Net Income | 784.13K | 3.32M | 3.51M | 13.81M | 6.05M | -4.05M |
Balance Sheet | ||||||
| Total Assets | 76.85M | 75.49M | 71.28M | 46.90M | 42.87M | 12.69M |
| Cash, Cash Equivalents and Short-Term Investments | 6.10M | 7.58M | 11.35M | 18.85M | 16.08M | 9.47M |
| Total Debt | 17.34M | 11.97M | 11.02M | 1.71M | 5.06M | 718.02K |
| Total Liabilities | 31.49M | 27.89M | 32.84M | 11.99M | 16.79M | 3.47M |
| Stockholders Equity | 46.11M | 48.20M | 38.78M | 34.98M | 26.10M | 9.30M |
Cash Flow | ||||||
| Free Cash Flow | 1.38M | 2.58M | 6.21M | 8.78M | 13.13M | 1.01M |
| Operating Cash Flow | 1.48M | 2.67M | 7.00M | 9.71M | 13.50M | 1.07M |
| Investing Cash Flow | -4.95M | -13.87M | -13.20M | -837.72K | 2.00M | -160.69K |
| Financing Cash Flow | 2.18M | 7.43M | -1.30M | -6.10M | -1.50M | -262.03K |
Cronos Australia Ltd. Technical Analysis
Cronos Australia Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | AU$31.81M | 40.00 | 7.64% | 3.28% | 0.13% | -12.90% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$4.14M | -1.09 | -26.84% | ― | 36.60% | 85.28% | |
46 Neutral | AU$10.12M | -1.50 | -469.43% | ― | -1.25% | -188.33% | |
39 Underperform | AU$9.53M | -0.24 | -401.36% | ― | -26.49% | 61.72% |
Cronos Australia Ltd. Corporate Events
Vitura Health Limited has scheduled an investor webinar to present its H1 FY2026 financial results and operational progress. The session, led by key board and executive members, will cover company highlights, financials, leadership updates, and an operational overview, signalling a structured effort to engage investors and clarify its current performance and strategic positioning.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health reported half-year FY2026 revenue of $67.9 million, up 8.3% year on year, driven by growth in medicinal cannabis distribution, nicotine vaping products and a 25% rise in digital consultation and service fees. The company’s Canview platform increased unit sales of medicinal cannabis by 10.6%, and its nicotine vaping line exceeded expectations with an average six‑month growth rate above 16% and its first million‑dollar revenue month.
Despite revenue gains, normalised EBITDA fell to $1.9 million and the company swung to a $1.0 million net loss, reflecting price and margin compression in medicinal cannabis and higher doctor costs. In response, Vitura has restructured management, reduced operational expenditure by 10% to deliver $2.8 million in annualised savings, advanced leadership changes and integrated its clinics under a unified Specialty Clinics division to stabilise margins and improve performance in the second half of FY2026 and beyond.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited will host an investor webinar at 9:00am AEDT on 26 February 2026 to present its half-year financial results for the period ended 31 December 2025. The online session will include a results presentation followed by a Q&A segment, giving investors direct access to management and further insight into the company’s operational performance and strategic direction.
The update comes as Vitura continues to expand its integrated digital health platform, spanning medicinal cannabis distribution, nationwide telehealth services and a growing focus on psychedelics. The half-year results briefing is likely to provide stakeholders with clarity on how these diversified assets are contributing to revenue, market positioning and the scalability of its end-to-end healthcare ecosystem.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited, formerly Cronos Australia Ltd., operates in the Australian medicinal cannabis sector with a core focus on product distribution through its Canview platform and complementary clinical and telehealth services. The company has expanded its footprint via acquisitions such as Candor Medical and Doctors on Demand, strengthening its presence in specialty clinics and B2B telehealth.
For the half-year to 31 December 2025, Vitura grew revenue 8% to $67.9 million but swung to a net loss attributable to members of $0.8 million, driven by industry-wide price compression and lower gross margins. Product revenue rose 4% while medical consultation and service fees jumped 25%, aided by a full half-year contribution from Candor and strong growth in Doctors on Demand’s B2B telehealth business, though the group’s average gross margin declined to 22.7% amid competitive discounting.
Operating expenses increased 11% to $16.1 million due largely to higher personnel costs following acquisitions, partly offset by significant IT savings after the purchase of the Canview platform and tighter cost management. The company capitalised further development on its Canview and Doctors on Demand platforms, expects these investments and its higher-margin clinic operations to stabilise margins, and chose not to declare an interim dividend after paying a full-year dividend in 2025.
Vitura’s cash balance fell 20% to $6.1 million as working capital needs and platform investment outpaced operating cash inflows, while trade receivables and inventories increased with growth and prepaid stock. Total liabilities rose 13% following a new $3 million ANZ banking facility to bolster liquidity, and cash outflows from investing eased sharply due to the absence of new acquisitions, reflecting a shift from deal-making to optimising existing assets and technology platforms.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has updated its corporate Trading Policy in line with ASX Listing Rule requirements, and the revised policy is now available on the company’s website. The change underscores Vitura’s focus on governance and compliance as it scales its digital health and medicinal cannabis operations across Australia.
The policy revision comes as Vitura expands its integrated platforms spanning medicinal cannabis distribution, nationwide telehealth, and psychedelic products through joint ventures. This governance update may support stakeholder confidence and align internal trading conduct with the company’s growing role in regulated therapeutic markets.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has notified the market that 2,316,848 performance rights have lapsed after the conditions attached to those rights were not met or became incapable of being satisfied, effective 28 January 2026. The cessation of these securities reduces the company’s pool of potential future equity dilution, providing greater clarity for existing shareholders regarding the current capital structure, although it may also signal that certain performance or strategic milestones underpinning these rights were not achieved.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health has announced the immediate departure of CEO Geoff Cockerill as the board seeks leadership better aligned with its push for improved financial and operational performance and the next phase of its transformation. Chief Revenue Officer Ryan Tattle will oversee day-to-day operations as interim leader, with all executive team members reporting to him, while non-executive director Shane Tanner steps into an Interim Executive Director role to support execution of performance improvement initiatives until at least 30 April 2026. The board has begun an advanced search for a new, execution-focused CEO, and confirmed that incoming CFO Andrew Cook, who brings more than two decades of senior international finance experience, will join the business earlier than expected on 9 February 2026. Chair Robert Iervasi said the company’s strategic priorities remain unchanged, emphasising operational excellence, financial discipline and consolidation of Vitura’s position as a trusted healthcare services provider, signalling continuity of strategy despite the top leadership reshuffle.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.06 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has notified the market that 1,931,081 performance rights have lapsed because the conditions attached to those rights were not, or could no longer be, satisfied. The cessation of these conditional securities reduces the pool of potential equity issuance, which may slightly affect future dilution outcomes for existing shareholders but does not change the company’s outstanding ordinary share capital.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has appointed experienced finance executive Andrew Cook as its new Chief Financial Officer, with the Queensland-based Chartered Accountant expected to commence in the role in the third quarter of FY2026. With more than two decades of senior finance experience across major organisations including Energy Queensland, Origin Energy, SABMiller and most recently as CFO and Company Secretary of AnteoTech Limited, Cook is expected to strengthen Vitura’s financial leadership as it pursues its strategic priorities in digital health, medicinal cannabis distribution and psychedelic therapies, supporting the company’s efforts to scale its integrated health platforms and deliver long-term value to shareholders.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has lodged its amended company constitution with the ASX, formalising changes approved by shareholders at the company’s 26 November 2025 Annual General Meeting, after a delay attributed to an administrative oversight. While the filing itself is procedural, it completes the governance step endorsed by investors and underscores the company’s efforts to align its corporate framework with its evolving digital health and medicinal products platform, which spans medicinal cannabis distribution, telehealth services, and a growing foothold in regulated psychedelic therapies, potentially strengthening its position in Australia’s rapidly developing digital and specialty healthcare markets.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has announced the cessation of 4.5 million unexercised options after their expiry on 16 December 2025, comprising three tranches of 1.5 million options each with exercise prices of $0.27, $0.34 and $0.41. The lapse of these options, which expired without being converted into shares, slightly simplifies Vitura Health’s capital structure and removes a potential source of future equity dilution for existing shareholders.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has disclosed a late lodgement of an Appendix 3Y notice relating to director Gerard Fogarty’s participation in the company’s dividend reinvestment plan, after an administrative oversight meant the securities issued on 30 September 2025 were not reported at the time. The company said the notice was filed promptly once the error was identified, described the incident as isolated, and reaffirmed that its existing reporting and notification processes remain adequate to ensure compliance with ASX director disclosure rules, signalling limited operational or governance impact for shareholders and other stakeholders.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited announced the appointment of Michael Sapountzis as its new Company Secretary, replacing Tom Howitt, who will remain as Chief Financial Officer until January 12, 2026. This leadership change aligns with Vitura’s operational priorities as it continues to advance its presence in the digital healthcare and medicinal cannabis markets. The move strengthens governance and administrative functions, positioning the company for future growth in its integrated healthcare systems.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.
Vitura Health Limited has announced the formation of an Industry Advisory Group to enhance its clinical governance and patient experiences. Chaired by Gerard Fogarty, the group will advise on medical practice management and emerging opportunities in the medicinal cannabis and specialty clinics industry, aiming to maintain industry-leading standards and improve patient outcomes.
The most recent analyst rating on (AU:VIT) stock is a Hold with a A$0.07 price target. To see the full list of analyst forecasts on Cronos Australia Ltd. stock, see the AU:VIT Stock Forecast page.